1. Patient must be at elevated risk for breast cancer, with more than 20% lifetime risk calculated by any one of the known risk models (Gail, Claus, Tyrer-Cusick or Hughes models) or based on a personal history of lobular carcinoma in situ (LCIS) or atypical hyperplasia.